Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R. Rimawi MF, et al. Among authors: kent osborne c. Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7. Breast Cancer Res Treat. 2018. PMID: 29110152 Free PMC article. Clinical Trial.
Molecular profiles of progesterone receptor loss in human breast tumors.
Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Creighton CJ, et al. Among authors: kent osborne c. Breast Cancer Res Treat. 2009 Mar;114(2):287-99. doi: 10.1007/s10549-008-0017-2. Epub 2008 Apr 19. Breast Cancer Res Treat. 2009. PMID: 18425577 Free PMC article.
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, Ademuyiwa F, Frith A, Ma C, Park H, Rigden C, Suresh R, Ellis M, Kent Osborne C, Rimawi MF. Niravath P, et al. Among authors: kent osborne c. Breast Cancer Res Treat. 2019 Sep;177(2):427-435. doi: 10.1007/s10549-019-05319-4. Epub 2019 Jun 19. Breast Cancer Res Treat. 2019. PMID: 31218477 Clinical Trial.
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Mazumdar A, et al. Among authors: kent osborne c. Breast Cancer Res Treat. 2016 Aug;158(3):441-54. doi: 10.1007/s10549-016-3892-y. Epub 2016 Jul 8. Breast Cancer Res Treat. 2016. PMID: 27393618 Free PMC article.